Revolution Medicines stock is trading -6.85% below its average target price of $47.0 after marking a 10.6% during today's afternoon session. Analysts are giving the Mid-Cap Biotechnology company an average rating of buy and target prices ranging from $40.0 to $63.0 per share.
Revolution Medicines has an average level of shares sold short, at 10.0% of its total share float. The stock's short ratio (also called days to cover) is 13.5. Since 2.39% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests.
Institutional investors own 98.9% of Revolution Medicines's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Revolution Medicines
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 9% | 14,757,112 | $646,066,345 |
| 2024-03-31 | Wellington Management Group, LLP | 9% | 14,714,726 | $644,210,686 |
| 2024-03-31 | Blackrock Inc. | 7% | 12,308,002 | $538,844,312 |
| 2024-03-31 | Baker Brothers Advisors, LLC | 5% | 7,549,249 | $330,506,112 |
| 2024-03-31 | Farallon Capital Management LLC | 5% | 7,507,872 | $328,694,626 |
| 2024-03-31 | Nextech Invest Ag | 4% | 6,296,740 | $275,671,269 |
| 2024-03-31 | BVF Inc. | 4% | 5,981,212 | $261,857,454 |
| 2024-03-31 | Casdin Capital, LLC | 3% | 5,617,599 | $245,938,477 |
| 2024-03-31 | State Street Corporation | 3% | 5,386,020 | $235,799,949 |
| 2024-03-31 | Alphabet Inc. | 3% | 5,301,512 | $232,100,188 |
